Primary Polydipsia Clinical Trial
Official title:
Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia: "The GOLD-Study"
Glucagon like Peptide -1 (GLP-1) receptor agonists are well known to stimulate glucose-induced insulin secretion and to reduce energy intake. Recent findings from animal and human studies suggest a role of GLP-1 in regulating water and salt homeostasis. GLP-1 has been shown to reduce fluid intake after an oral salt load or during a meal - pointing to a hypodipsic effect. The aim of this study is to elucidate whether these putative hypodipsic properties of GLP-1 might be of advantage in persons with an exaggerated thirst perception as is the case in patients with primary polydipsia.
GLP-1 analogues are currently used for the treatment of hyperglycaemia associated with type 2
diabetes mellitus and given his properties as a natural satiety hormone, the GLP-1 analogue
liraglutide was recently approved by the FDA for weight management.
In studies related to the influence of GLP-1 and -analogues in controlling food intake a
concomitant reduction of fluid consumption has been observed.
The investigators hypothesize that GLP-1 analogues not only modulate appetite and provide
satiety but also reduce fluid intake and thirst sensation in humans - especially in those
with excessive thirst perception (patients with primary polydipsia). In view of future
therapeutic options for these patients we aim to investigate the influence of the long-acting
GLP-1 analogue dulaglutide on fluid intake, thirst perception and quality of life in patients
with primary polydipsia compared to placebo.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05890690 -
Plasma Copeptin in Response to Oral Urea in Healthy Adults and Patients With Polyuria-polydipsia Syndrome
|
N/A | |
| Completed |
NCT01940614 -
Use of Copeptin in Diabetes Insipidus
|